Lowest-Rated Stocks NASDAQ:IONS Ionis Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.02 -0.54 (-1.44%) (As of 06/30/2022 04:00 PM ET) Add Compare Share Today's Range$36.68▼$37.7650-Day Range$31.71▼$42.3452-Week Range$25.04▼$44.42Volume774,263 shsAverage Volume1.12 million shsMarket Capitalization$5.25 billionP/E RatioN/ADividend YieldN/APrice Target$43.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock Forecast (MarketRank)Overall MarketRank™1.86 out of 5 starsMedical Sector733rd out of 1,433 stocksPharmaceutical Preparations Industry350th out of 684 stocksAnalyst Opinion: 2.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 2.1 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 1 hold rating, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.44, Ionis Pharmaceuticals has a forecasted upside of 17.4% from its current price of $37.02.Amount of Analyst CoverageIonis Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesIonis Pharmaceuticals has received 651 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIonis Pharmaceuticals has received 410 “underperform” votes. (Add your “underperform” vote.)Community SentimentIonis Pharmaceuticals has received 61.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote “Outperform” if you believe IONS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $302,085.00 in company stock.Percentage Held by InsidersOnly 2.36% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions95.16% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($2.40) to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -185.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -185.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.Read More IONS Stock News HeadlinesJune 28, 2022 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Hold" by AnalystsJune 25, 2022 | markets.businessinsider.comIonis : GSK Presents Positive Phase 2b Data For Chronic Hepatitis B TreatmentJune 25, 2022 | finance.yahoo.comIonis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™June 25, 2022 | americanbankingnews.comIonis Pharmaceuticals, Inc. to Post Q2 2022 Earnings of ($0.56) Per Share, William Blair Forecasts (NASDAQ:IONS)June 23, 2022 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) PT Raised to $27.00 at SVB LeerinkJune 21, 2022 | benzinga.comRecap of Tuesday's Biotech Catalysts - End of the Day SummaryJune 21, 2022 | finance.yahoo.comAstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this yearJune 21, 2022 | investing.comAstraZeneca and Ionis drug for rare disease achieves positive trial dataJune 19, 2022 | americanbankingnews.comShort Interest in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Decreases By 16.1%June 13, 2022 | seekingalpha.comIonis therapy for Angelman syndrome granted key FDA designationsJune 13, 2022 | finance.yahoo.comIonis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDAJune 12, 2022 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) PT Raised to $55.00 at Piper SandlerJune 9, 2022 | americanbankingnews.comTheStreet Lowers Ionis Pharmaceuticals (NASDAQ:IONS) to DSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees660Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/30/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$43.44 High Stock Price Forecast$65.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+17.4%Consensus RatingHold Rating Score (0-4)2.125 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.200010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28.60 million Net Margins-0.36% Pretax Margin-0.41% Return on Equity-0.46% Return on Assets-0.12% Debt Debt-to-Equity Ratio1.76 Current Ratio9.86 Quick Ratio9.76 Sales & Book Value Annual Sales$810 million Price / Sales6.48 Cash Flow$0.09 per share Price / Cash Flow416.92 Book Value$5.47 per share Price / Book6.77Miscellaneous Outstanding Shares141,798,000Free Float138,452,000Market Cap$5.25 billion OptionableOptionable Beta0.78 Ionis Pharmaceuticals Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2022? 8 analysts have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their IONS stock forecasts range from $26.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $43.44 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Ionis Pharmaceuticals' stock price performed in 2022? Ionis Pharmaceuticals' stock was trading at $30.43 at the beginning of the year. Since then, IONS stock has increased by 21.7% and is now trading at $37.02. View the best growth stocks for 2022 here. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Ionis Pharmaceuticals. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.22. The firm had revenue of $142 million for the quarter, compared to analyst estimates of $122.46 million. Ionis Pharmaceuticals had a negative net margin of 0.36% and a negative trailing twelve-month return on equity of 0.46%. Ionis Pharmaceuticals's quarterly revenue was up 26.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. View Ionis Pharmaceuticals' earnings history. What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $612.37 million. Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the following people: Dr. Brett P. Monia Ph.D., Founder, CEO & Director (Age 61, Pay $1.32M)Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 60, Pay $869.38k) (LinkedIn Profile)Ms. Onaiza Cadoret-Manier, Exec. VP and Chief Product Strategy & Operations Officer (Age 57, Pay $755.52k)Mr. Patrick R. O'Neil Esq., Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 48, Pay $815.69k)Dr. Stanley T. Crooke, Scientific Advisor (Age 77, Pay $1.64M)Ms. B. Lynne Parshall Esq., J.D., Sr. Strategic Advisor & Director (Age 68, Pay $701.77k) (LinkedIn Profile)Dr. Eric E. Swayze Ph.D., Exec. VP of Research (Age 56, Pay $739.3k)Mr. Joel Edwards, VP of Corp. Operations (Age 61)Mr. Darren Gonzales, Chief Accounting Officer & Sr. VPDr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 65) Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of IONS's competitors. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $37.02. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.25 billion and generates $810 million in revenue each year. The company earns $-28.60 million in net income (profit) each year or ($0.200010) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? Ionis Pharmaceuticals employs 660 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for Ionis Pharmaceuticals is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
